-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 17, the official website of NMPA showed that Yuxi Jiahe Biotechnology Co.
Infliximab is a human-mouse chimeric monoclonal antibody developed by Johnson & Johnson/Mersk that specifically blocks tumor necrosis factor (TNF-α).
The drug was first approved by the FDA in the United States in 1998, approved in Europe the following year, and approved in China in 2006 under the trade name of Leike®
Although it has been on the market in China for many years, the first infliximab biosimilar has just been approved in July 2021, from Taizhou Maibotec Pharmaceuticals
Among several TNF-α antibody drugs, adalimumab is the most competitive as the “Drug King”.
Competition details of key biosimilars (in Insight database, as of February 17, 2022)